- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01870505
BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
2022년 3월 1일 업데이트: Memorial Sloan Kettering Cancer Center
A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
The purpose of this study is to test the safety of a drug called BYL719 at different dose levels.
The investigators want to find out what effects, good and/or bad, BYL719 has on the patient and breast cancer.
BYL719 will be given with either letrozole or exemestane to patients with HR+ locally-advanced or metastatic breast cancer.
When the recommended phase II dose of BYL719 in combination with letrozole or exemestane has been determined in the dose-finding phase, an additional 10 patients will be enrolled onto each arm in an expansion phase of the study.
The purpose of the expansion phase is to further define the safety and feasibility of BYL719 in combination with letrozole or exemestane at the recommended phase II dose, and to estimate efficacy.
연구 개요
상태
완전한
개입 / 치료
연구 유형
중재적
등록 (실제)
52
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
New York
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
여성
설명
Inclusion Criteria:
- Women age ≥ 18 years
- Willing and able to comply with scheduled visits, treatment plan and laboratory tests
- Willing and able to consent for biopsy of locally-advanced or metastatic breast cancer prior to treatment
- Metastatic or locally-advanced unresectable breast cancer (includes metastatic or locally-advanced unresectable breast cancer which is diagnosed while on adjuvant letrozole or exemestane)
- Histologically documented HR+ breast cancer in either the primary or metastatic setting, as defined by ER or PR ≥ 1%; results from the local lab are acceptable. Eligibility will not be affected by HER2 status.
- The most recent treatment prior to enrollment must be one of the following (duration of treatment ≥2 weeks), and must have been adequately tolerated according the treating physician's judgment:
- Letrozole
- Exemestane
- Exemestane + everolimus (everolimus must be discontinued for ≥ 3 weeks prior to starting study treatment)
- Letrozole or exemestane in combination with an experimental agent(s) on a clinical trial, provided that the experimental agent(s) is not a PI3K inhibitor or AKT inhibitor (experimental agent(s) must be discontinued for ≥ 3 weeks prior to starting study treatment)
- Any number of prior endocrine therapies (including tamoxifen, fulvestrant and/or aromatase inhibitors in either the adjuvant or metastatic setting) and any number of prior chemotherapy regimens. Anti-cancer systemic therapy, such as chemotherapy or biologics or endocrine therapy, other than the AI, must be discontinued for ≥ 3 weeks prior to starting study treatment.
- For the dose-finding phase, patients must also have stable disease OR progression of disease on the most recent treatment. For the expansion phase, patients must have progression of disease on the most recent treatment. Progression of disease is defined as new or worsening disease on objective imaging. Progression of disease includes recurrence diagnosed while on adjuvant letrozole or exemestane.
- Postmenopausal women, as defined by one of the following (estradiol assay cutoff takes into account that the patient is on aromatase inhibitor therapy):
- Age ≥ 55 years and one year or more of amenorrhea
- Age < 55 years and one year or more of amenorrhea, with an estradiol assay within the post-menopausal range
- Age < 55 years with prior hysterectomy but intact ovaries, with an estradiol assay within the post-menopausal range
- Surgical menopause with bilateral oophorectomy
- Ovarian suppression with a LH-RH agonist, with an estradiol assay within the post-menopausal range at baseline and periodically on-study Measurable or non-measurable disease per RECIST criteria v1.1
- ECOG performance status 0-1
- Adequate organ function, as defined by all of the following:
Hematologic parameters:
- Absolute neutrophil count (ANC) ≥ 1500/μl (without growth factor support)
- Platelets ≥ 100,000/μl (no transfusion allowed within 2 weeks)
- Hemoglobin ≥ 9.0 g/dl (may be reached by transfusion)
- Liver function:
- Serum bilirubin ≤ 1.5 x upper limit of normal (ULN) unless attributable to Gilbert's syndrome
- AST ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present
- ALT ≤ 2.5 x ULN, or ≤ 5 x ULN if liver metastases are present
Kidney function:
- Creatinine ≤ 1.5 ULN
- Endocrine function:
- Fasting plasma glucose <140 mg/dl (may be on antiglycemic agents other than insulin). Fasting glucose measurement must be obtained at least 8 hours after the most recent caloric intake.
- Ability to swallow oral medication
- Willing to discontinue all herbal preparations / medications at least 7 days prior to the first dose of study drug and throughout the study. These include, but not limited to,St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.
Exclusion Criteria:
- Pregnant patients or women who are breast-feeding (patients must be postmenopausal, see Section 6.1.9)
Patients with central nervous system (CNS) involvement may participate if:
- Clinically stable with respect to the CNS tumor at the time of screening and >4 weeks from prior therapy completion (including radiation and/or surgery) to the start of study treatment
- Not receiving steroid therapy
- Not receiving enzyme inducing anti-epileptic medications that were started for brain metastases (these include carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine, topiramate, and vigabatrin) Prior PI3K inhibitor or AKT inhibitor (patients previously treated with everolimus are eligible, see rationale in Section 3.6)
- History of toxicity to the most recent AI (letrozole or exemestane) that warrants cessation of the AI
- Patients who have received radiotherapy ≤ 2 weeks prior to starting study treatment
- Patients who have undergone major surgery ≤ 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedure
- Uncontrolled diabetes (as defined by fasting glucose ≥ 140mg/dL) and/or insulin-dependent diabetes. Fasting glucose measurement must be obtained at least 8 hours after the most recent caloric intake. Patients currently requiring the use of antiglycemic agents (other than insulin) may be enrolled if fasting glucose <140mg/dL.
- Current need for chronic corticosteroid therapy (≥10mg of prednisone daily or an equivalent dose of other corticosteroid), or patients who have received systemic corticosteroids ≤ 2 weeks prior to starting study drug
- Current therapeutic anticoagulation with warfarin (or coumarin derivatives) Active infection or serious underlying medical condition that would impair the patient's ability to receive protocol treatment
- Clinically significant cardiac disease or impaired cardiac function, such as:
- Congestive heart failure requiring treatment (e.g., New York Heart Association Class II, III or IV) Acute coronary syndromes < 3 months prior to screening (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting)
- Uncontrolled arterial hypertension defined by blood pressure > 140/100 mm Hg at rest (average of 3 consecutive readings)
- History or current evidence of unstable, clinically significant cardiac arrhythmias or patients that require medications with a narrow therapeutic window, atrial fibrillation and/or conduction abnormality, e.g. congenital long QT syndrome, high-Grade/complete AV-blockage
- Corrected QT interval (QTc) > 480 msec on screening ECG Patients who are currently receiving medication with a known risk of prolonging the QT interval or inducing Torsades de Pointes (TdP) and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug treatment (see Section 9.6.3 and Appendix F)
- Impaired gastrointestinal function or poorly controlled gastrointestinal disease that may significantly alter the absorption of oral BYL719 (e.g. Crohn's disease, ulcerative colitis, malabsorption syndrome, small bowel resection, uncontrolled nausea or vomiting, or grade ≥ 3 diarrhea of any etiology) based on treating physician assessment
- Patients may not have a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Arm A: BYL719 plus Letrozole
For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added.
A treatment cycle will consist of 28 days.
Treatment doses for each AI will be fixed at the established dose.
Patients will continue on treatment until progression of disease or unacceptable toxicity.
The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
|
|
실험적: Arm B: BYL719 plus Exemestane
For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added.
A treatment cycle will consist of 28 days.
Treatment doses for each AI will be fixed at the established dose.
Patients will continue on treatment until progression of disease or unacceptable toxicity.
The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
|
|
실험적: Arm C: BYL719 plus Letrozole
For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle.
The starting dose of BYL719 in Arms C will be 250mg daily.
Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
|
|
실험적: Arm D: BYL719 plus Exemestane
For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.
Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle.
For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study.
Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
phase II dose of BYL719 (Arm A and Arm B)
기간: 2 years
|
Three patients will be enrolled onto Cohort 0 at the starting BYL719 dose of 300mg daily.
All patients within a cohort will be observed for toxicity for one cycle (28 days) prior to entering additional patients.
|
2 years
|
phase II dose of BYL719 (Arm C and Arm D)
기간: 2 years
|
For Arms C and D, the starting dose of BYL719 for the first cohort (Cohort 0) will be 250mg daily.when
administered in combination with letrozole in a 1 week on, 1 week off schedule, or with exemestane in a 5 of 7 days weekly schedule, to patients with HR+ locally-advanced or metastatic breast cancer
|
2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
safety and tolerability of BYL719 (Arm A, B, C and D)
기간: 2 years
|
Toxicity will be tabulated using the NCI Common Toxicity Criteria (CTCAE), version 4.0.
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as at least possibly related to the study medication, meeting any of the criteria listed in the table below, and occurring during Cycle 1 (≤ 28 days following the first dose of BYL719, including those in which the event started in Cycle 1 and the confirmation of the DLT occurs in a subsequent cycle).
|
2 years
|
efficacy of BYL719 (Arm A and Arm B)
기간: 2 years
|
Progression-free survival
|
2 years
|
efficacy of BYL719 (Arm C and Arm D)
기간: 2 years
|
in two distinct schedules, plus letrozole or exemestane, in patients with HR+ locally-advanced or metastatic breast cancer, by calculation of the following in an expansion cohort:. Progression-free survival
|
2 years
|
evaluate mechanisms of acquired resistance (Arms A, B, C and D)
기간: 2 years
|
with correlative studies of on-treatment and optional post-progression tumor biopsies
|
2 years
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 수석 연구원: Sarat Chandarlapaty, MD, PhD, Memorial Sloan Kettering Cancer Center
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2013년 5월 1일
기본 완료 (실제)
2022년 2월 28일
연구 완료 (실제)
2022년 2월 28일
연구 등록 날짜
최초 제출
2013년 6월 3일
QC 기준을 충족하는 최초 제출
2013년 6월 3일
처음 게시됨 (추정)
2013년 6월 6일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2022년 3월 2일
QC 기준을 충족하는 마지막 업데이트 제출
2022년 3월 1일
마지막으로 확인됨
2022년 3월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 13-027
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
바일719에 대한 임상 시험
-
Novartis Pharmaceuticals종료됨재발성 두경부 편평 세포 암종 | 전이성 두경부 편평 세포 암종프랑스, 대만, 미국, 호주, 캐나다, 홍콩, 싱가포르, 대한민국, 네덜란드
-
Novartis Pharmaceuticals완전한폐경 전 유방암 | PI3K 경로 억제대만, 홍콩, 태국, 대한민국
-
Centre Hospitalier Universitaire DijonNovartis Pharmaceuticals모병Megalencephaly-모세관 기형 Polymicrogyria 증후군 (MCAP)프랑스
-
Novartis Pharmaceuticals완전한
-
Novartis Pharmaceuticals완전한유방암캐나다, 이탈리아, 체코, 미국, 벨기에, 오스트리아, 독일, 스페인, 일본, 레바논, 호주, 불가리아, 이스라엘, 네덜란드, 콜롬비아, 홍콩, 브라질
-
Dana-Farber Cancer InstituteNovartis; AstraZeneca완전한
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)모집하지 않고 적극적으로IV기 유방암 | 재발성 유방암 | 에스트로겐 수용체 양성 유방암 | 프로게스테론 수용체 양성 유방암 | HER2 음성 유방암 | 침윤성 유관 유방 암종미국
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)완전한해부학적 III기 유방암 AJCC v8 | 해부학적 IIIA기 유방암 AJCC v8 | 해부학적 IIIB기 유방암 AJCC v8 | 해부학적 병기 IIIC 유방암 AJCC v8 | 예후 III기 유방암 AJCC v8 | 예후 IIIA기 유방암 AJCC v8 | 예후 IIIB기 유방암 AJCC v8 | 예후 IIIC기 유방암 AJCC v8 | 해부학적 4기 유방암 AJCC v8 | 예후 IV기 유방암 AJCC v8 | 재발성 유방암 | HER2/Neu 음성 | 삼중음성 유방암 | 진행성 유방암 | 안드로겐 수용체 양성 | 전이성 유방암 | PTEN 포지티브 | 난치성 유방암미국
-
University of ArizonaNational Cancer Institute (NCI)종료됨HPV 양성 구인두 편평 세포 암종 | IVA기 구인두 편평 세포 암종 AJCC v7 | 3기 구인두 편평 세포 암종 AJCC v7 | CDKN2A-p16 양성 | 1기 구인두 편평 세포 암종 AJCC V7 | II기 구인두 편평 세포 암종 AJCC V7미국